par MEDIAN TECHNOLOGIES (EPA:ALMDT)
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Press release – For immediate release
February 11, 2026 – 5:45 pm CET
Disclosure of total number of voting rights and number of shares in the capital as of January 31, 2026
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Sophia Antipolis, France
| Total number of shares | 36,948,314 |
| Number of real voting rights* (excluding treasury shares**) | 36,878,376 |
| Theoretical number of voting rights* (including treasury shares**) | 36,925,114 |
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Contacts
Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press – Ulysse Communication
Bruno Arabian
+33 6 87 88 47 26
barabian@ulysse-communication.com
Nicolas Entz
+33 6 33 67 31 54
nentz@ulysse-communication.com
Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com